Abstract

Malaria is a parasitic tropical disease that kills around 600,000 patients every year. The emergence of resistant Plasmodium falciparum parasites to artemisinin-based combination therapies (ACTs) represents a significant public health threat, indicating the urgent need for new effective compounds to reverse ACT resistance and cure the disease. For this, extensive curation and homogenization of experimental anti-Plasmodium screening data from both in-house and ChEMBL sources were conducted. As a result, a coherent strategy was established that allowed compiling coherent training sets that associate compound structures to the respective antimalarial activity measurements. Seventeen of these training sets led to the successful generation of classification models discriminating whether a compound has a significant probability to be active under the specific conditions of the antimalarial test associated with each set. These models were used in consensus prediction of the most likely active from a series of curcuminoids available in-house. Positive predictions together with a few predicted as inactive were then submitted to experimental in vitro antimalarial testing. A large majority from predicted compounds showed antimalarial activity, but not those predicted as inactive, thus experimentally validating the in silico screening approach. The herein proposed consensus machine learning approach showed its potential to reduce the cost and duration of antimalarial drug discovery.

Highlights

  • Malaria is a major tropical parasitic disease that each year affects 500 million humans worldwide and kills 600,000 patients, in particular children younger than five years-old and pregnant women inSub-Saharan Africa

  • Considering the numerous evidences that curcuminoids, and DAAs, are potent antimalarial products, we focused our interest on this series

  • Extensive data curation and fusion was primordial to the extraction of large modelable structure-activity sets, in a context characterized by an extreme heterogeneity of reported antimalarial assay protocols

Read more

Summary

Introduction

Malaria is a major tropical parasitic disease that each year affects 500 million humans worldwide and kills 600,000 patients, in particular children younger than five years-old and pregnant women inSub-Saharan Africa. Thousands of merozoites are subsequently produced and invade erythrocytes to initiate the intraerythrocytic cycle. Some of the merozoites develop into gametocytes that are taken by the mosquito during feeding, and the cycle is repeated. Digestion of host hemoglobin during the erythrocytic cycle is an important process for providing amino acids for parasitic development. The parasite detoxifies free heme as side product of hemoglobin digestion by bio-mineralization into the malarial pigment called hemozoin [1,2]. This heme detoxification is the target pathway of numerous antimalarial drugs, most of them belonging to the aminoquinoline series [3]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call